|
Sunday, December 4 - Welcome & Opening
|
| 09:00 - 14:00 |
Exhibition set-up |
| 14:00 - 17:00 |
Opening of the registration desk |
| 15:30 - 16:00 |
Welcome reception |
| SESSION I - Natural Peptides To Drugs |
| 16:00 - 16:15 |
Opening ceremony & Welcome notes |
| 16:15 - 16:50 |
Opening Lecture: Prof. Richard D. DI MARCHI
The pursuit of transformational medicines
Indiana University, USA |
| 16:50 - 17:50 |
ORAL PRESENTATIONS |
| 16:50 - 17:10 |
Prof. Martin KUSSMANN
Nutritional peptidomics: Food bioactives and their health effects
Nestlé Institute of Health Sciences & Aarhus University, Switzerland & Denmark
|
| 17:10 - 17:30 |
Dr Mark SMYTHE
Exploiting disulfid-rich peptides in drug discovery
Protagonist Therapeutics Inc & University of Queensland, Australia |
| 17:30 - 17:50 |
Dr Simon CHELL
Constructing ultra long half-life peptides and proteins using AlbudAbs
GlaxoSmithKline, United Kingdom |
| 17:50 - 18:05 |
MINI BREAK |
| 18:05 - 18:40 |
Invited Lecture: Prof. Glenn F. KING
Development of a high-throughput pipeline for venoms-based drug discovery
University of Queensland, Australia |
| 18:40 - 19:10 |
LIFT PRESENTATIONS (5 minutes each, business oriented) |
| |
Dr Pierre ESCOUBAS
Development of a parallel refolding platform for disulfide-linked peptide toxins
VenomeTech, France |
| |
Dr Agnes M. JAULENT
Selection of peptide scaffolds using CIS-display technology
Isogenica Ltd, United Kingdom |
| |
Dr Ulrich REINEKE
Novel neurotensin-based radio-tracers for imaging and therapy of ductal pancreatic adenocarcinoma
3B Pharmaceuticals GmbH, Germany |
| |
Mr Christian SCHüTZ
Pharmaceutical formulation development of synthetic peptides
Bachem AG, Switzerland |
|
Prof. Vladislav DEIGIN
Two reciprocal therapeutics from one EW - peptide family
Shemyakin&Ovchinnikov Institute of Bioorganics Chemistry RAS, Russia
|
| 20:00 - ... |
SWISS-EVENT DINNER |
|
Monday, December 5 - From Natural Peptides
|
|
SESSION II - Drug Discovery (1)
|
| 08:15 - 08:50 |
Invited Lecture: Prof. Michel LAZDUNSKI
Venom peptides against pain
CNRS & Theralpha SAS, France |
| 08:50 - 09:30 |
ORAL PRESENTATIONS |
| 08:50 - 09:10 |
Prof. Richard LEWIS
Establishment of a high throughput assay for the discovery of new Nav1.7 modulators from venoms
University of Queensland, Australia |
| 09:10 - 09:30 |
Prof. Christian HEINIS
Phage selection of bicycle peptide antagonists
Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland |
| 09:30 - 10:00 |
COFFEE BREAK |
|
SESSION III - Drug Discovery (2)
|
| 10:00 - 10:35 |
Invited Lecture: Prof. Daniel BERTRAND
The importance of small peptides in ion channels drug discovery
HiQScreen, Switzerland |
| 10:35 - 11:15 |
ORAL PRESENTATIONS |
| 10:35 - 10:55 |
Dr Reto STÖCKLIN
NextGen Venomics: lead discovery in natural, synthetic and virtual venoms
Atheris Laboratories, Switzerland |
| 10:55 - 11:15 |
Prof. Baldomero M. OLIVERA
Accessing the most challenging molecular targets in the nervous system using cone snail venom peptides
University of Utah, USA |
| 11:15 - 16:30 |
ORGANISED RECREATIONAL ACTIVITIES
LUNCH BREAK |
| 16:30 - 17:00 |
WELCOME BACK SPECIAL |
|
SESSION IV - Structure-Function & Modelling
|
| 17:00 - 17:35 |
Invited Lecture: Dr Ronald V. SWANSON
Venom peptide engineering: Increasing throughput for drug discovery
Johnson & Johnson Pharmaceutical Research & Development, USA |
| 17:35 - 18:15 |
ORAL PRESENTATIONS |
| 17:35 - 17:55 |
Prof. Michael GUREVITZ
Mapping the receptor sites of scorpion toxins at voltage-gated sodium channels
Tel-Aviv University, Israel |
| 17:55 - 18:15 |
Prof. Emanuel ESCHER
Discovery of potent synthetic agonists for the CXCR4 chemokine receptor by a NP2D approach
University of Sherbrooke, Canada |
| 18:15 - 18:30 |
MINI BREAK |
|
SESSION V - Lead Validation
|
| 18:30 - 19:05 |
Invited Lecture: Prof. Matthias TSCHÖP
Gut peptides as the basis for combinatorial treatment of obesity & diabetes
Helmholz Centre & Technical University, Germany |
| 19:05 - 19:45 |
ORAL PRESENTATIONS |
| 19:05 - 19:25 |
Prof. Paul ALEWOOD
Oxytocin agonist development – a selenocysteine mimetic reveals a functional selectivity switch for the human oxytocin receptor
University of Queensland, Australia |
| 19:25 19:45 |
Dr Bart LANDUYT
A novel endogenous peptide identified in the pancreas enhances learning behavior and inhibits neuro degeneration
University of Leuven, Belgium |
| 20:00 - ... |
FREE EVENING |
|
Tuesday, December 6 - Through Development
|
|
SESSION VI - Early Development - Metabolic Diseases & Oncology
|
| 08:15 - 08:50 |
Invited Lecture: Dr Andrew BUTLER
Assessment of a candidate for developing a peptide-based drug (adropin) for treating obesity-related metabolic disorders
The Scripps Research Institiute, USA |
| 08:50 - 09:50 |
ORAL PRESENTATIONS |
| 08:50 - 09:10 |
Dr Graham COTTON
The development of ALM201 – a novel peptide derived from the natural anti-angiogenic protein FKBPL with potent anti-tumour activity
Almac Sciences, United Kingdom |
| 09:10 - 09:30 |
Dr Murali RAMACHANDRA
Aurigene-012 as a novel peptide inhibitor of the PD-1 signalling pathway: identification of a preclinical drug candidate for cancer therapy
Aurigene Discovery Technologies Ltd, India |
| 09:30 - 09:50 |
Sponsored by Peptides & Elephants: Dr Carsten GRÖTZINGER
Short chemerin analogues for tumor targeting
Charité Univesitätsmedizin Berlin, Germany |
| 09:50 - 10:20 |
COFFEE BREAK |
|
SESSION VII - Peptide Leads & The Immune System
|
| 10:20 - 10:55 |
Invited Lecture: Dr Michael PENNINGTON
Advancing ShK peptide into the clinic for treatment of multiple sclerosis
Peptides International Inc. & The Toxinomics Foundation, USA & Switzerland
|
| 10:55 - 11:35 |
ORAL PRESENTATIONS |
| 10:55 - 11:15 |
Dr Sonia TROEIRA HENRIQUES
The anti-HIV activity of the cyclotide kalata B1 is explained by peptide-membrane interactions
Universities of Queensland & Lisbon, Australia & Portugal |
| 11:15 - 11:35 |
Dr Daniel SAMSON
Synthetic manufacturing of aprotinin a small protein API
Bachem AG, Switzerland
|
| 11:35 - 12:05 |
HOT-SPOT PRESENTATIONS (5 minutes each) |
| |
Prof. Günter ALLMAIER
Digging for hidden treasures: investigating yet unexplored snake venoms
Vienna University of Technology, Austria |
| |
Mr Dominique KOUA
TATools, a bioinformatic platform for in depth transcriptome analysis
Atheris Laboratories, Switzerland
|
| |
Prof. Robin OFFORD
A project born at NP2D: an interim report
Mintaka Foundation for Medical Research, Switzerland
|
| |
Prof. Peter VERHAERT
Men and frogs: the peptidomics connection
Delft University of Technology & BioMedical Research Center, The Netherlands & Belgium |
| 12:05 - 13:30 |
LUNCH BREAK |
| 13:30 - 17:00 |
OPTIONAL ACTIVITIES & NETWORKING SESSIONS |
|
SESSION VIII - Bioavailability & Selectivity
|
| 17:00 - 17:35 |
Invited Lecture: Prof. James P. TAM
Engineering proteinaceous natural product as orally active bradykinin antagonists
Nanyang Technological University, Singapore |
| 17:35 - 19:00 |
ROUND-TABLE: Cell penetrating peptides |
| 17:40 - 17:55 |
Dr Michel DE WAARD
Biotechnology value of maurocalcine for the cell delivery of compounds of imaging and therapeutic interest
Smartox Biotechnologies & Inserm, France |
| 17:55 - 18:10 |
Prof. Paul WATT
Phylomer libraries for the discovery of novel scaffolds suitable for intracellular or extracellular targets
Phylogica Ltd., Australia |
| 18:10 - 18:25 |
Dr Hanjo HENNEMANN
Intracellular screening for peptide drugs to access non-enzymatic intracellular targets
Nexigen, Germany |
| 18:25 - 18:40 |
Dr Dennis J. CHURCH
Tissue selective cell penetrating peptides for targeted drug delivery
The Toxinomics Foundation & Vector LifeSciences, Switzerland
|
| 18:40 - 19:00 |
Open debate: Can cell penetrating peptides be potent and selective?
Moderated by Peter Hoffmann & Reto Stöcklin |
| 20:00 - ... |
GALA DINNER |
|
Wednesday, December 7 - To Clinics
|
|
SESSION IX - Peptide Drug Design, Synthesis & Manufacturing
|
| 08:15 - 08:50 |
Invited Lecture: Dr Claudio D. SCHTEINGART
Oxytocin and vasopressin : a bounty of drugs from two natural peptides
Ferring Research Institute Inc., USA |
| 08:50 - 09:50 |
ORAL PRESENTATIONS |
| 08:50 - 09:10 |
Dr Donald WELLINGS
Novel polymer supports for solid phase peptide synthesis and applications beyond
Spheritech Ltd, United Kingdom |
| 09:10 - 09:30 |
Dr Mimoun AYOUB
Peptide manufacturing strategies, technical, regulatory, environment and economical key considerations
Peptisyntha (Solvay group), Belgium |
| 09:30 - 09:50 |
Dr Georges GAUDRIAULT
Controlled release of peptides using MedinGel technology
MedinCell SA, France |
| 09:50 - 10:20 |
COFFEE BREAK |
|
SESSION X - Peptide Drug Development - Oral & Inhalation
|
| 10:20 - 10:55 |
Invited Lecture: Dr Angelika FRETZEN
Development of linaclotide as a guanylate cyclase-c receptor agonist for the treatment of irritable bowel syndrome with constipation
Ironwood Pharmaceuticals Inc., USA |
| 10:55 - 11:35 |
ORAL PRESENTATIONS |
| 10:55 - 11:15 |
Dr Odile SELLIER-KESSLER
Discovery of POL6014: a potent Protein Epitope Mimetic (PEM)-inhibitor of HNE for the treatment of COPD
Polyphor Ltd, Switzerland |
| 11:15 - 11:35 |
Dr Kelly KRAFT
Inhaled tetrapeptides as novel pain therapies
MannKind Corporation, USA |
| 11:35 - 12:10 |
Closing Lecture: Dr Thomas VORHERR
Discovery of peptide therapeutics
Novartis Pharma AG, Switzerland |
|
12:10 - 12:25
|
Closing Notes
|
| 12:25- ... |
FAREWELL COCKTAIL / LUNCHEON |
